{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:28:31Z","timestamp":1722893311725},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2004,9,21]],"date-time":"2004-09-21T00:00:00Z","timestamp":1095724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1038\/sj.bjc.6602176","type":"journal-article","created":{"date-parts":[[2004,9,21]],"date-time":"2004-09-21T09:18:39Z","timestamp":1095758319000},"page":"1428-1433","source":"Crossref","is-referenced-by-count":1,"title":["Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil"],"prefix":"10.1038","volume":"91","author":[{"name":"on behalf of the Gruppo Italiano Studio Carcinomi Apparato Digerente (GISCAD)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Guglielmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Barni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Pella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Belvedere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G D","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Frontini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Labianca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Sobrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,9,21]]},"reference":[{"key":"BF6602176_CR1","first-page":"1016","volume":"22","author":"T Andr\u00e9","year":"2003","unstructured":"Andr\u00e9 T, Figer A, Cervantes A, Lledo G, Flesch M, Maindrault-Goebel F, Mineur L, Russ G, Buyse M, De Gramont A (2003) FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized optimox study. Proc Am Soc Clin Oncol 22: 1016","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/bjc.1998.53","volume":"177","author":"C Aschele","year":"1998","unstructured":"Aschele C, Guglielmi A, Frassineti GL, Milandri C, Amadori D, Labianca R, Vinci M, Tixi L, Caroti C, Ciferri E, Verdi E, Rosso R, Sobrero A (1998) Schedule selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study. Br J Cancer 177: 341\u2013346","journal-title":"Br J Cancer"},{"key":"BF6602176_CR3","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jnci\/94.16.1191","volume":"94","author":"J Baldwin","year":"2002","unstructured":"Baldwin J (2002) FDA evaluating oxaliplatin for advanced colorectal cancer treatment. J Natl Cancer Inst 94: 1191\u20131193","journal-title":"J Natl Cancer Inst"},{"key":"BF6602176_CR4","first-page":"1088","volume":"22","author":"J Bennouna","year":"2003","unstructured":"Bennouna J, Perrier H, Paillot B, Priou F, Jacob JH, Hebbar M, Bordenave S, Seitz JF, Tonelli D, Douillard JY (2003) Tegafox, a new combination of UFT\/LV and oxaliplatin as first line treatment for patients with non resectable metastatic colorectal cancer: results of a completed multicenter phase II trial. Proc Am Soc Clin Oncol 22: 1088","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR5","first-page":"741","volume":"19","author":"M Borner","year":"2000","unstructured":"Borner M, Schsffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Peters G, Grynwald V, Wanders J, de Boer R, Mrtin C, Fumoleau P (2000) A randomized crossover trial comparing oral UFT (Uracil\/tegafur)+leucovorin (LV) and intravenous fluorouracil (FU)+LV for patient preference and pharmacokinetics in advanced colorectal cancer. Proc Am Soc Clin Oncol 19: 741","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/annonc\/mdf089","volume":"13","author":"J Cassidy","year":"2002","unstructured":"Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL, Capecitabine Colorectal Cancer Study Group (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil\/leucovorin. Ann Oncol 13: 566\u2013575","journal-title":"Ann Oncol"},{"key":"BF6602176_CR7","first-page":"502","volume":"21","author":"D Cunningham","year":"2002","unstructured":"Cunningham D, de Gramont A, Scheitauer W, Smakal M, Humblet Y, Kurteva G, Iveson T, Andre T, Dostalova J, Illes A, Jia X, Palmer P (2002) Randomized double-blind placebo-controlled trial of farnesyltransferase inhibitor R115777 (Zamestra) in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol 21: 502","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR8","first-page":"6","volume":"26","author":"D Cunningham","year":"1999","unstructured":"Cunningham D, Glimelius B (1999) A phase III study of irinotecan (CPT-11) vs best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 26: 6\u201312","journal-title":"Semin Oncol"},{"key":"BF6602176_CR9","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment of advanced colorectal cancer. J Clin Oncol 18: 2938\u20132947","journal-title":"J Clin Oncol"},{"key":"BF6602176_CR10","first-page":"1372","volume":"15","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 15: 1372\u20131379","journal-title":"Lancet"},{"key":"BF6602176_CR11","first-page":"2529","volume":"4","author":"JL Fischel","year":"1998","unstructured":"Fischel JL, Etienne MC, Formento P, Milano G (1998) Search for optimal schedule for the oxaliplatin\/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 4: 2529\u20132535","journal-title":"Clin Cancer Res"},{"key":"BF6602176_CR12","first-page":"503","volume":"21","author":"BJ Giantonio","year":"2002","unstructured":"Giantonio BJ, Levy D, Catalano P, O'Dwyer PJ, Benson AB (2002) Incorporating angiogenesis inhibition with bevacizumab (anti VEGF) into front-line chemotherapy with irinotecan (CPT-11), fluorouracil and leucovorin (FU\/LV) for advanced colorectal cancer (advCRC): a toxicity analysis of ECOG study E2200. Proc Am Soc Clin Oncol 21: 503","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR13","first-page":"1009","volume":"22","author":"RM Goldberg","year":"2003","unstructured":"Goldberg RM, Morton RF, Sargent DJ, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP (2003) N9741: oxaliplatin (Oxal) or CPT-11+5-fluorouracil(5-FU)\/leucovorin (LV) or oxal+CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Proc Am Soc Clin Oncol 22: 1009","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR14","first-page":"512","volume":"21","author":"A Grothey","year":"2002","unstructured":"Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzschmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll HJ (2002) Phase III study of bolus 5-fluorouracil (5-FU)\/folinic acid (FA) (Mayo) vs weekly high-dose 24\u2009h 5-FU infusional\/FA+oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21: 512","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR15","first-page":"1022","volume":"22","author":"A Grothey","year":"2003","unstructured":"Grothey A, Jordan K, Kellner O, Costantin C, Dittrich G, Kroening H, Mantovani L, Schlichting C, Forstbauer H, Schmoll HJ (2003) Randomized phase II trial of capecitabine plus irinotecan (CapIRI) vs capecitabine plus oxaliplatin (CapOX) as first-line therapy for advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 22: 1022","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR16","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1200\/JCO.2003.02.071","volume":"21","author":"H Hochster","year":"2003","unstructured":"Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuc-Jacquotte A, Muggia F (2003) Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol 21: 2703\u20132707","journal-title":"J Clin Oncol"},{"key":"BF6602176_CR17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1054\/bjoc.1999.1254","volume":"82","author":"DJ Jonker","year":"2000","unstructured":"Jonker DJ, Maroun JA, Kocha W (2000) Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomised trial. Br J Cancer 82: 1789\u20131794","journal-title":"Br J Cancer"},{"key":"BF6602176_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457\u2013458","journal-title":"J Am Stat Assoc"},{"key":"BF6602176_CR19","first-page":"537","volume":"21","author":"J King","year":"2002","unstructured":"King J, Clingan P, Morris DL (2002) Placebo-control double-blind randomised clinical trial of the matrix metalloproteinase inhibitor (MMP) marimastat in patients with inoperable colorectal cancer liver metastases (CRCLM): significant survival advantage in patients with musculoskeletal symptoms. Proc Am Soc Clin Oncol 21: 537","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR20","first-page":"991","volume":"19","author":"RD Knight","year":"2000","unstructured":"Knight RD, Miller LL, Pirotta N, Elfring GL, Locker PK, Saltz LB (2000) First-line irinotecan (C), fluorouracil (F), leucovorin (L) especially improve survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favourable prognostic indicators. Proc Am Soc Clin Oncol 19: 991","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/jnci\/85.1.41","volume":"85","author":"CG Leichman","year":"1993","unstructured":"Leichman CG, Leichman L, Spears CP, Rosen PJ, Jeffers S, Groshen S (1993) Prolonged infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 85: 41\u201344","journal-title":"J Natl Cancer Inst"},{"key":"BF6602176_CR22","first-page":"558","volume":"20","author":"F Levi","year":"2001","unstructured":"Levi F, Zigani L, Coudert B, Antoine E, Cajfinger F, Rocher M, Coeffic D, Spano J, Taillibert S, Bismuth H, Khayat D (2001) Chronomodulated irinotecan (I)\u2013Fluorouracil (F)\u2013Leucovorin (L)\u2013Oxaliplatin (O) (CHRONO IFLO) as salvage therapy in patients with heavily pretreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 20: 558","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","volume":"15","author":"G Liu","year":"1997","unstructured":"Liu G, Franssen E, Fitch M, Warner E (1997) Patient preferences for oral vs intravenous palliative chemotherapy. J Clin Oncol 15: 110\u2013115","journal-title":"J Clin Oncol"},{"key":"BF6602176_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1200\/JCO.1991.9.3.371","volume":"9","author":"JC Marsh","year":"1991","unstructured":"Marsh JC, Bertino JR, Katz KH, Davis CA, Durivage HJ, Rome LS, Richards II F, Capizzi RL, Farber LR, Pasquale DN (1991) The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9: 371\u2013380","journal-title":"J Clin Oncol"},{"key":"BF6602176_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207\u2013214","journal-title":"Cancer"},{"key":"BF6602176_CR26","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1200\/JCO.2002.08.144","volume":"20","author":"A Ravaioli","year":"2002","unstructured":"Ravaioli A, Marangolo M, Pasquini E, Rossi A, Amadori D, Cruciani G, Tassinari D, Oliverio G, Giovanis P, Turci D, Zumaglini F, Nicolini M, Panzini I (2002) Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol 20: 2545\u20132550","journal-title":"J Clin Oncol"},{"key":"BF6602176_CR27","first-page":"7","volume":"20","author":"L Saltz","year":"2001","unstructured":"Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, LoBuglio A (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20: 7","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602176_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"28","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blande C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 28: 905\u2013914","journal-title":"N Engl J Med"},{"key":"BF6602176_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1\u201310","journal-title":"Control Clin Trials"},{"key":"BF6602176_CR30","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/jnci\/85.23.1937","volume":"85","author":"A Sobrero","year":"1993","unstructured":"Sobrero A, Aschele C, Guglielmi A, Mori AM, Melioli GG, Rosso R, Bertino JR (1993) Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 85: 1937\u20131944","journal-title":"J Natl Cancer Inst"},{"key":"BF6602176_CR31","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1054\/bjoc.2001.1732","volume":"84","author":"A Sobrero","year":"2001","unstructured":"Sobrero A, Guglielmi A, Cirillo M, Recaldin E, Frassineti GL, Aschele C, Ravaioli A, Testore P, Caroti C, Gallo L, Pessi MA, Cortesi E, Turci D, Grossi F, Labianca R (2001) 5-Fluorouracil modulated by leucovorin, methotrexate and mytomicin: highly effective, low-cost chemotherapy for advanced colorectal cancer. Br J Cancer 84: 1023\u20131028","journal-title":"Br J Cancer"},{"key":"BF6602176_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1026527605389","volume":"11","author":"A Sobrero","year":"2000","unstructured":"Sobrero A, Zaniboni A, Frassineti GL, Aschele C, Guglielmi A, Giuliani R, Ravaioli A, Lanfranco C, Caroti C, Arnoldi E, Barni S, Gallo L, Pessi MA, Turci D, Cortesi E, Grossi F, Frontini L, Piazza E, Bruzzi P, Labianca R (2000) Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers. Ann Oncol 11: 1\u20138","journal-title":"Ann Oncol"},{"key":"BF6602176_CR33","first-page":"955","volume":"1","author":"AF Sobrero","year":"1995","unstructured":"Sobrero AF, Aschele C, Guglielmi A, Mori AM, Tixi LM, Bolli EA, Rosso R, Mammoliti S, Rollandi GA, Bertoglio S (1995) Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer. Clin Cancer Res 1: 955\u2013960","journal-title":"Clin Cancer Res"},{"key":"BF6602176_CR34","first-page":"1023","volume":"22","author":"E Van Cutsem","year":"2003","unstructured":"Van Cutsem E, Twelves C, Tabernero J, Schoffski P, Figer A, Diaz-Rubio E, De Braud F, Conroy T, Cassidy J, Butts C, on behalf of XELOX phII investigators (2003) XELOX: mature results of a multinational, phase II trial of capecitabine plus oxaliplatin, an effective 1st line option for patients with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 22: 1023","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602176","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:13:00Z","timestamp":1684411980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,21]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["BF6602176"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602176","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2004,9,21]]}}}